Naming, Switching, and Interchangeability of Biosimilars

Activity Details
  • Credit Amounts:
    • CME: 0.25
    • CNE: 0.28
  • Cost: Free
  • Release: Jul 26, 2019
  • Expires: Jul 25, 2020
  • Estimated Time to Complete:
    15 Minutes
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Release date: July 27, 2019
Expiration date: July 27, 2020
Estimated time to complete: 15 minutes




Faculty

Jonathan Kay Jonathan Kay, MD (Activity Chair)
Professor of Medicine
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Director of Clinical Research, Division of Rheumatology
University of Massachusetts Medical School
Worcester, MA

Alissa Segal Alissa Segal, PharmD, CDE, CDTC, FCCP
Professor of Pharmacy Practice
Program Director of the School of Pharmacy (Boston) Doctor of Pharmacy Honors Program
MCPHS University
Clinical Pharmacist
Joslin Diabetes Center
Boston, MA

Needs Statement

The safety and interchangeability of biosimilars presents a growing concern for clinicians. In this video, Jonathan Kay, MD, and Alissa Segal, PharmD, discuss the naming of biosimilars, interchangeability in pharmacy-level substitutions, and the potential impact of biosimilars on access to treatment, cost, and patient outcomes.

 

Target Audience

This activity is designed specifically for primary care clinicians, nurses, and other members of the healthcare team.

 

Objectives

Discuss the role of biosimilars and their impact on access to treatment, cost utility, and patient outcomes

 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Talem MedEd. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly provided by Talem MedEd.

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Contact Hours: 0.28 of which 0.28 is eligible for pharmacology credit

 

Faculty Disclosure

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.


FACULTY

Jonathan Kay, MD, has disclosed the following relationships: consultant for AbbVie Inc., Boehringer Ingelheim GmbH, Celltrion Healthcare Co. Ltd., Merck Sharp &  Dohme Corp., Novartis Pharmaceuticals, Pfizer Inc., Roche Laboratories, Inc., Samsung Bioepis, Sandoz Inc., and UCB, Inc.; and research support (paid to the University of Massachusetts Medical School) from Gilead Sciences Inc., Pfizer Inc., and UCB, Inc.

Alissa R. Segal, PharmD, CDE, CDTC, FCCP, has no relevant financial conflicts to disclose.

Faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.


PLANNING COMMITTEE

The following planning committee members for this activity have no relevant financial relationships to disclose:

Jennifer Brittonā€Colonnese, RN, NP, CNE Course Advisor, Boston University School of Medicine
Joanna Krause, MPH, Program Manager, Boston University School of Medicine, CME/CNE
Carmela Townsend, DNP, MS/MBA, RN, Lead Nurse Planner, Boston University School of Medicine, CME/CNE
Jason M. Worcester, MD, CME Course Director, Boston University School of Medicine
Erica Rusie, PharmD, Scientific Director, Scientific Affairs, Talem Health, LLC

 

Acknowledgment

This activity is supported by an educational grant from Pfizer.

 

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTHCARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY OR TALEM HEALTH BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.

©Talem Health, LLC 2019. All Rights Reserved.

 

Contact Us

For questions regarding this CME/CE activity, please contact:
Lauren Wills by phone, 800-913-9370 ext. 705 or email, lwills@talemhealth.com

 

How To Obtain Credit

  • Follow instructions to register or log in with your professional information
  • Watch the entire video
  • Complete and submit the online evaluation
  • A certificate of participation will be available for download/printing immediately following your successful completion of the evaluation